News
12-12-2009, 06:10 AM
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly-owned subsidiary, BiPar Sciences, announced that the clinical development program in metastatic triple-negative breast cancer (mTNBC) for the investigational PARP1 inhibitor, BSI-201, progresses as planned with the Phase 3 study meeting expectations on patient accrual and trial site coverage in the United States...
More... (http://www.medicalnewstoday.com/articles/173854.php)
More... (http://www.medicalnewstoday.com/articles/173854.php)